MTSL Issue 858 (dated 8/17/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #ANTH #BMRN #ESPR #FPRX #INCY #IONS #MDCO #MDGL #NKTR #PCRX #SGMO #XON #ZIOP
MTSL Issue 856 (dated 7/13/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #BMRN #IONS #INCY #XON #NKTR #SGMO
MTSL Issue 854 (dated 6/15/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ESPR #INCY #XON #NKTR #FPRX #ZIOP
BioInvest News – IONS – Reports Positive TTR Data, Safety/Patient Death Causes Concern – IONS reported positive Phase III data for inotersen (TTR-Rx) NEURO-TTR results in familial amyloid polyneuropathy (FAP) patients showing a statistically significant benefit in the two co-primary endpoints of modified Neuropathy Impairment Score (mNIS+7, p<0.0001) and the Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QOL-DN, P=0.0006) post 15 months of treatment.
MTSL Issue 857 (dated 7/27/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ALKS #ESPR #INCY #IONS #MDCO #NKTR #NVAX #PCRX
Intrexon (XON) has had a very busy few weeks as the company has delivered a slew of positive news, explains John McCamant, editor of The Medical Technology Stock Letter.
MTSL Issue 853 (dated 6/01/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #BMRN #IONS #NKTR
Complimentary Issue (dated 5/04/17) of Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: ALKS BMRN CELG ESPR FPRX INCY IONS MDCO PCRX SGMO ZIOP
BioInvest News – NVAX – Delivers Some Positive Phase II Immunogenicity Data In COPD…Investors Wanted an RSV Update – NVAX reported top line data from the Phase II older adult safety and immunogenicity trial (E205) demonstrated the benefit of adjuvant formulations and two-dose regimens in patients with RSV and chronic obstructive pulmonary disease (COPD).
MTSL Issue 855 (dated 6/29/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ALKS #ESPR #SGMO #ZIOP
MTSL Issue 852 (dated 5/18/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #INCY #XON #IONS #NKTR #NVAX #SGMO #ZIOP
Breaking News – Sangamo Therapeutics (SGMO) – PFE Global Deal for Hemophilia A Has Many Positive Implications – In a very competitive bidding process SGMO has inked a significant global partnership with Pfizer, who brings a wealth of value to SGMO, and notably validates the latter company’s gene therapy platform.
